<DOC>
	<DOC>NCT00073255</DOC>
	<brief_summary>To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).</brief_summary>
	<brief_title>Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>To be eligible participants will have Type 1 diabetes, diagnosed within the previous 12 months and established by standard American Diabetes Association criteria. All participants will have autoantibodies: either antiGAD65, antiICA512, or if treated with insulin for less than 7 days, antiinsulin. The age range will be between 8 and 30 years; and a minimum weight of 34 kg.</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>